Illumina (NASDAQ:ILMN – Get Rating) will report results after the market close on Tuesday, February 7. Analysts expect the company to report earnings of $0.25 per share for the quarter. Illumina has set FY22 guidance at EPS of $2.35 to $2.50 and FY22 guidance at EPS of $2.35 to $2.50. Investors interested in attending the company’s conference call can do so using this link.
→ Become an investor in Brooklyn Gin (From UNKNOWN)
Illumina (NASDAQ:ILMN – Get Rating) last reported earnings on Thursday, November 3rd. The life sciences company reported his EPS of $0.34 for the quarter, $0.05 above analyst consensus expectations of $0.29. The company posted revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.1 billion. Illumina’s return on equity was 4.36% and net profit margin was 88.40%. On average, analysts expect Illumina to report EPS of $2 in the current fiscal year and $1 in the next fiscal year.
Illumina deal fell 1.8%
ILMN opened Tuesday for $210.10. The stock has a market cap of $33.05 billion, a PE ratio of -7.96 and a beta of 1.13. The company has a quick ratio of 0.72, a current ratio of 0.93 and a debt to equity ratio of 0.07. His 50-day moving average for this business is $206.17 and his 200-day moving average is $208.46. Illumina has a 52-week low of $173.45 and a 52-week high of $371.16.
Illumina Insider Trading
In separate news, SVP Aimee L. Hoyt sold 871 shares of the company in a transaction on Monday, January 9th. Her shares sold at an average price of $205.57, giving her a total of $179,051.47. Post-transaction, the senior vice president now owns 2,796 shares of the company directly, valued at approximately $574,773.72. The transaction was disclosed in documents filed with the SEC and can be accessed at this link. In related news, her senior vice president, Aimee L. Hoyt, sold 871 shares of her stake in Illumina on Monday, January 9. The shares sold for an average of $205.57, and the total transaction value was her $179,051.47. After the transaction, the senior vice president now owns 2,796 shares of the company directly, valued at $574,773.72. The deal is disclosed in documents filed with the Securities and Exchange Commission and available on the SEC’s website. Also, SVP girlfriend Susan H. Tousi sold 500 shares of Illumina stock on Tuesday, December 6th. The shares were sold at an average price of $212.63, giving her a total of $106,315.00. After the transaction, the senior vice president now owns 39,162 shares of the company’s stock valued at $8,327,016.06. Please see here for the disclosure of this sale. Insiders have sold 2,371 shares of her company stock worth $499,481 in the last 90 days. The insider owns her 0.13% of the company’s shares.
Hedge funds look to Illumina
Institutional investors and hedge funds are buying and selling stocks these days. Acadian Asset Management LLC upped his Illumina stock position by 312.5% in the first quarter. Acadian Asset Management LLC now owns 2,013 shares of the life sciences company worth $702,000 after he acquired an additional 1,525 shares last quarter. Dimensional Fund Advisors LP increased his position in Illumina stock by 3.1% in the first quarter. Dimensional Fund Advisors LP owns 237,118 shares of life sciences companies valued at $82,853,000 after acquiring an additional 7,114 shares in the previous quarter. Dakota Wealth Management increased his position in Illumina stocks by 13.8% in the first quarter. Dakota Wealth Management now owns 826 shares of life sciences companies valued at $288,000 after acquiring another 100 shares last quarter. Sequoia Financial Advisors LLC increased his Illumina stock position by 16.9% in the first quarter. Sequoia Financial Advisors LLC owns 803 shares of life sciences companies valued at $281,000 after acquiring an additional 116 shares in the previous quarter. Finally, Baird Financial Group Inc. increased his Illumina stock position by 10.2% in the first quarter. Baird Financial Group Inc. now owns 48,943 shares of life sciences companies valued at $17,108,000 after acquiring an additional 4,548 shares in the previous quarter. 87.97% of the shares are currently owned by hedge funds and other institutional investors.
Wall Street analyst opinion
A number of research analysts have recently commented on the ILMN stock. Cowen lowered Illumina’s price target from his $350.00 to his $296.00 in a research note on Tuesday, Jan. 10. Citigroup downgraded Illumina from a “neutral” rating to a “sell” rating in a research report on Monday, Dec. 12, and he lowered the company’s price target from $200.00 to $180.00. Bank of America lowered its price target for Illumina from $220.00 to $210.00 in a research report on Tuesday, January 10. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in its research report on Tuesday, December 20. Finally, Scotiabank began reporting on Illumina in his Wednesday, January 4 investigative report. They set a “sector perform” rating and a price target for the company of $216.00. Two equity research analysts gave the stock a sell rating, six assigned a hold rating, and eight issued a buy rating to the company. According to MarketBeat data, the stock has an average rating of ‘Hold’ and a consensus price target of $252.32.
About Illumina
(get rating)
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company operates through its Core Illumina segment, which serves customers in the research, clinical, and applied market segments and enables the adoption of a variety of Genomic His solutions.
References
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to contact@marketbeat.com.
Hear this before you consider Illumina.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Illumina wasn’t on the list.
Illumina currently has a “hold” rating among analysts, but top-rated analysts believe these five stocks are better buys.
See 5 stocks here
